Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.59 |
| ▸ | EGFR | P00533 | 13/20 | 0.59 |
| ▸ | FLT1 | P17948 | 9/20 | 0.57 |
| ▸ | FLT4 | P35916 | 6/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.54 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579205 | 0.92 | KDR (0.69) | KDREGFRFLT1FLT4FGFR1 | |
| SCHEMBL4580086 | 0.91 | KDR (0.58) | KDREGFRFLT1 | |
| SCHEMBL4578144 | 0.91 | EGFR (0.61) | KDREGFR | |
| SCHEMBL4577936 | 0.90 | KDR (0.51) | KDREGFRFLT1FLT4FGFR1 | |
| SCHEMBL4578311 | 0.90 | EGFR (0.58) | KDREGFRFLT1FLT4FGFR1 | |
| SCHEMBL4578816 | 0.90 | KDR (0.58) | KDREGFR | |
| SCHEMBL4577370 | 0.88 | EGFR (0.59) | KDREGFR | |
| SCHEMBL5091094 | 0.88 | KDR (0.62) | KDREGFRFLT1FLT4FGFR1 | |
| SCHEMBL4577898 | 0.87 | KDR (0.60) | KDREGFR | |
| SCHEMBL4578314 | 0.86 | EGFR (0.58) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | KDR 1226/4885EGFR 955/4885FLT1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.